More support for prenatal MVMs
This article was originally published in The Tan Sheet
Executive Summary
Continued improvements in the infant and maternal mortality rates will depend on interventions before a woman becomes pregnant, according to officials from the March of Dimes, CDC and other experts. "Preconception Care for Improving Perinatal Outcomes: The Time to Act," was published Sept. 19 as part of the Maternal & Child Health Journal. The supplement includes the use of multivitamins with folic acid to prevent birth defects. Recently the Canadian Health Food Association promoted multivitamin compliance as a way to reduce healthcare costs, (1"The Tan Sheet" Sept. 11, 2006, In Brief)...
You may also be interested in...
CHFA on multivitamins
The Canadian Health Food Association is using a recently published meta-analysis of multivitamin use and the prevention of birth defects to promote multivitamin compliance as a way to reduce healthcare costs, according to a Sept. 1 release from the trade group. "Research continues to show that multivitamins are a simple, cost-effective way to support improved immune function and help prevent chronic disease," CHFA President Valerie Bell says in the release. The study in the August Journal of Obstetrics & Gynecology of Canada finds use of folic-acid containing prenatal multivitamins was associated with a decreased risk for several congenital anomalies, not only neural tube defects, according to Y. Ingrid Goh, Department of Pharmaceutical Sciences, University of Toronto, Canada, et al. The authors suggest reconsidering the current approach of recommending only folic acid in light of their research. In May, a panel convened by NIH determined current data was "insufficient" to make a conclusive recommendation for or against the use of multivitamins in the prevention of chronic diseases (1"The Tan Sheet" May 22, 2006, p. 6)...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.